{"id":"bol-303242-x","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"}]},"_chembl":{"chemblId":"CHEMBL2103876","moleculeType":"Small molecule","molecularWeight":"462.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the S1P1 receptor, BOL-303242-X modulates sphingosine-1-phosphate signaling, which plays a crucial role in lymphocyte trafficking and immune response. This mechanism is thought to contribute to its therapeutic effects in treating inflammatory conditions.","oneSentence":"BOL-303242-X is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:23.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-infectious uveitis"}]},"trialDetails":[{"nctId":"NCT01163643","phase":"PHASE2","title":"Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-07","conditions":"Dry Eye Syndrome","enrollment":356},{"nctId":"NCT00905450","phase":"PHASE2","title":"Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-06","conditions":"Cataract, Inflammation","enrollment":415},{"nctId":"NCT01230125","phase":"PHASE3","title":"Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-11","conditions":"Cataract","enrollment":311},{"nctId":"NCT01298752","phase":"PHASE3","title":"Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery","status":"TERMINATED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-02","conditions":"Inflammation, Pain, Cataract","enrollment":177}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mapracorat"],"phase":"phase_2","status":"active","brandName":"BOL-303242-X","genericName":"BOL-303242-X","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BOL-303242-X is a small molecule glucocorticoid receptor agonist, classified as an agonist. It has been studied for the treatment of conditions including cataract, inflammation, dry eye syndrome, and pain, particularly in the context of cataract surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}